Comment from Elos Medtech’s Board of Directors regarding the public offer from TA Associates

Report this content

Today, June 11, 2021, TA Associates through EM Intressenter AB (“TA Associates”) announced a public offer of SEK 215 in cash per share to the shareholders of Elos Medtech AB (publ) (”Elos Medtech”) (the “Offer”).

Further information regarding the Offer is available in TA Associates’ press release issued today. An offer document regarding the Offer is expected to be published by the Offeror on or around June 11, 2021. See also The acceptance period for the Offer is expected to commence on or about June 14, 2021 and expire on or about July 5, 2021.

The Board of Directors of Elos Medtech has appointed Carnegie Investment Bank AB (publ) as financial advisor and Vinge as legal advisor in connection with the Offer. The board has also engaged Grant Thornton to provide a fairness opinion regarding the Offer. The Board of Directors, together with its advisors, will evaluate the Offer and will publish its opinion on the Offer at the latest two weeks prior to the end of the acceptance period.

Yvonne Mårtensson, Chair of the Board of Directors of Elos Medtech commented: “As announced on June 1, we have had a dialogue for some time regarding a possible offer for Elos Medtech. The Board will now thoroughly evaluate the offer and present its opinion to the shareholders in due course.”

Gothenburg, June 11, 2021

The Board of Directors of Elos Medtech AB (publ)

For further information, please contact:

Yvonne Mårtensson, Chairman of the Board, +4670 833 77 82, email:


For additional information about the Elos Medtech Group, visit

This is information that Elos Medtech AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on June 11, 2021, at 07:20 a.m. (CEST).